Werewolf Therapeutics reports progress on IBD treatment

WATERTOWN, Mass. - Werewolf Therapeutics, Inc. (NASDAQ:HOWL), a biopharmaceutical company specializing in immune system-stimulating therapeutics with a current market capitalization of $40.6 million, announced new findings for its IL-10 INDUKINE molecule, WTX-921, at IMMUNOLOGY2025. According to InvestingPro analysis, the company’s stock has seen significant volatility, falling 85% over the past year while showing recent signs of recovery with a 7% gain in the past week. The data presented shows that WTX-921 reduces tissue damage and inflammatory cytokine production in a mouse colitis model, advancing the understanding of its anti-inflammatory impact on the immune landscape in inflamed colon tissue.

The study, summarized in a poster titled "Development of WTX-921, A Conditionally Active IL-10 INDUKINE™ Molecule for the Treatment of Inflammatory Bowel Disease," builds on earlier proof-of-concept data and demonstrates the molecule’s potential as a targeted therapy for IBD. While the company advances its therapeutic pipeline, InvestingPro data reveals that Werewolf maintains a strong liquidity position with a current ratio of 7.45, indicating substantial cash reserves to fund its research programs. WTX-921 is engineered to minimize toxicities associated with systemic IL-10 delivery by being conditionally activated and selectively delivering native IL-10 to inflamed tissues.

Daniel J. Hicklin, Ph.D., President and CEO of Werewolf Therapeutics, stated that the results validate WTX-921’s potential to modulate disease-driving immune responses in IBD. The molecule is designed to address the limitations of current IL-10 therapies, which have shown promise but are often hindered by dose-dependent adverse events.

In preclinical trials, WTX-921 displayed efficacy in an ACT animal model of colitis over four weeks, preventing weight loss and reducing Disease Activity Index scores. It also inhibited inflammation by decreasing immune cell infiltration and the RNA levels of inflammatory cytokines in the colon of treated animals.

WTX-921 is part of Werewolf Therapeutics’ broader effort to develop conditionally activated molecules for cancer and other immune-mediated conditions. The company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are being developed for the treatment of solid tumors and Non-Hodgkin Lymphoma. With analysts maintaining a strong buy consensus and setting price targets between $4 and $15, investors seeking deeper insights can access comprehensive analysis and 10 additional key metrics through InvestingPro’s detailed research reports, available as part of their coverage of over 1,400 US equities.

The poster detailing WTX-921’s development is available for viewing on the Werewolf Therapeutics website. The findings are based on a press release statement and have not been independently verified.

In other recent news, Werewolf Therapeutics has maintained its Market Outperform rating with a price target of $4, according to analysts at JMP. The company has progressed in its clinical programs by selecting a recommended dose of WTX-124 for its ongoing trials. This dosage will be used both as a standalone treatment and in combination with pembrolizumab for several cancer types. Werewolf Therapeutics plans to provide an interim data update in the fourth quarter of 2025, which is expected to offer insights into the efficacy and safety of WTX-124. Additionally, the company intends to engage with the FDA in the second half of 2025 to discuss potential registration pathways, including accelerated approval options.

In another development, Werewolf Therapeutics has appointed Dr. Anil Singhal to its board of directors following the resignation of Dr. Derek DiRocco. Dr. Singhal brings over three decades of industry experience and will serve as a Class I director and on the Audit Committee. His compensation includes an annual cash fee and an option to purchase 45,000 shares of the company’s stock. These recent developments highlight Werewolf Therapeutics’ strategic planning and ongoing efforts in advancing its clinical programs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.